Clinical trials: Acute Non-Lymphocytic Leukemia
AML, Adult, Refractory AML
Study Investigating the Efficacy and Safety of the Addition of Oral-azacitidine to Salvage Treatment by Gilteritinib in Subjects ≥18 Years of Age With Relapsed/Refractory FLT3-mutated Acute Myeloid Leukemia
Approximately 30% of adult AML subjects are refractory to induction therapy. Furthermore, of those who achieve CR, approximately 75% will relapse. FLT3-mutated AML comprise an especially poor prognosis group.
- Conditions
- AML, Adult, Refractory AML, Relapsed Adult AML, FLT3-TKD Mutation
- Trial name
- OGILAR (NCT06022003)
- Testing
- AzaCITIDine Oral Tablet, Xospata
- Where
- 20 sites in France
- Volunteers
- 33 people
- Sponsor
- French Innovative Leukemia Organisation
Lymphoma, Acute Lymphatic Leukemia
Comparative Quantification of MTX and Its Metabolites Post Glucarpidase
Acidification (i.e., addition of hydrochloric acid) of plasma samples from patients who have received Glucarpidase post high-dose MTX treatment is regarded as a necessary preanalytic step to avoid further in vitro enzymatic…
- Trial name
- NCT05250869
- Testing
- HPLC/MS
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- Charite University, Berlin, Germany
Acute Myeloid Leukemia, Myelodysplastic Syndromes
ACHIEVE2 - Safety and Preliminary Efficacy of Intravenous TCB008 in Patients With Relapse or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)/AML
TCB008-003 (ACHIEVE2) is an open-label, multi-center study conducted in 2 parts (dose escalation followed by dose expansion) to evaluate safety, persistence/expansion, and preliminary efficacy of single and multiple intravenous…
- Trial name
- ACHIEVE2 (NCT06463327)
- Testing
- TCB008
- Volunteers
- 69 people
- Sponsor
- TC Biopharm
Acute Myeloid Leukemia
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
The primary purpose of the study is to determine, whether the addition of Sorafenib to standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results (event free survival).
- Trial name
- NCT00373373
- Testing
- Sorafenib
- Where
- 18 sites in Germany
- Volunteers
- 200 people
- Sponsor
- University Hospital Muenster
Relapsed or Refractory Acute Myeloid Leukemia
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
Recent preclinical and retrospective clinical data have suggested that dexamethasone might sensitize leukemic cells to chemotherapy-induced cell death and thus limit the risk of leukemic regrowth and relapse.
- Trial name
- DEXAML-03 (NCT03765541)
- Testing
- Dexamethasone, Amsacrine, Cytarabine
- Where
- 10 sites in France
- Volunteers
- 73 people
- Sponsor
- University Hospital, Toulouse
Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase
Haploid Allogeneic Transplant Using the CliniMACS System
To assess the proportion of patients with donor neutrophil engraftment within 30 days of allogeneic transplant. To assess the incidence of acute GvHD during the first 100 days after transplantation.
- Conditions
- Acute Myelogenous Leukemia (AML) - Relapsed, Primary Refractory Disease or Poor Risk Factors, Chronic Myelogenous Leukemia (CML) - Accelerated or Second Chronic Phase, Myelodysplastic Syndrome (MDS) - High and Intermediate Risk, Non-Hodgkin's Lymphoma (NHL)
- Trial name
- NCT00185679
- Testing
- CliniMACS System
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ginna Laport
Acute Myeloid Leukemia
Natural Killer (NK) Cell Transplantation for AML
The purpose of this study is to assess the safety and efficacy of infusing natural killer cells from a donor as treatment for patients with acute myeloid leukemia in remission or who have experienced relapse.
- Trial name
- NCT00187096
- Testing
- Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2, Natural Killer Cell Infusion, CliniMACS System
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- St. Jude Children's Research Hospital
Acute Myeloid Leukemia
Single Dose Study With 4SC-203 in Healthy Volunteers
The purpose of the study is to evaluate safety and tolerability of 4SC-203 after a single dose administration in healthy volunteers.
- Trial name
- NCT01054937
- Testing
- 4SC-203
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Acute Myeloid Leukemia (AML)
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and…
- Trial name
- NCT03047083
- Testing
- Treatment patterns among AML patients, AML-related healthcare resources
- Where
- United States
- Volunteers
- 1,027 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Detection of PCM1-JAK2 Fusion Gene by FISH in the Two Types of t-MDS/AML and Relationship Between PCM1-JAK2 Fusion Gene and Cumulative Dose, Dose Intensity
PCM1-JAK2 in Therapy Related Neoplasms
The term "therapy-related" leukemia is descriptive and is based on a patient's history of exposure to cytotoxic agents. Although a causal relationship is implied, the mechanism remains to be proven.
- Trial name
- NCT03943394
- Testing
- fresh samples are obtained from patients for detction of PCM1- JAK2 fusion gene
- Volunteers
- 140 people
- Sponsor
- Assiut University
Acute Myelogenous Leukemia
CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia
This phase Ib trial studies the best dose of gemtuzumab ozogamicin when given together with CPX-351 in treating patients with acute myeloid leukemia that has come back after it was previously in remission.
- Trial name
- NCT03904251
- Testing
- Gemtuzumab Ozogamicin, Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- 5 sites in United States
- Volunteers
- 13 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Leukemia, Lymphoma
FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of FR901228 in treating patients who have myelodysplastic…
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00042822
- Testing
- romidepsin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
B-cell Acute Lymphoblastic Leukemia
Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia
Modern therapy for patients with B-lineage acute lymphoblastic leukemia (ALL) is based on intensive administration of multiple drugs.
- Trial name
- NCT01974479
- Testing
- anti-CD19 redirected NK cells
- Where
- Singapore
- Volunteers
- 20 people
- Sponsor
- National University Health System, Singapore
Acute Myeloid Leukemia
NGS in AML Relapse
Acute myeloid leukemia (AML) relapse is often associated with a clonal evolution at the cytogenetic and molecular level and therefore represents a challenge in the treatment of AML.
- Trial name
- NGSAML (NCT03582241)
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Strasbourg, France
Leukemia
Studying DNA in Samples From Younger Patients With Down Syndrome and Acute Myeloid Leukemia Treated on COG-AAML0431 Clinical Trial
RATIONALE: Studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01507441
- Testing
- gene mapping, microarray analysis, mutation analysis
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Acute Myeloid Leukemia
Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia
This phase I trial evaluates the side effects of uproleselan, azacitidine, and venetoclax in treating older or unfit patients with treatment naive acute myeloid leukemia.
- Trial name
- NCT04964505
- Testing
- Azacitidine, Uproleselan, Venetoclax
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Brian Jonas
Leukemia, Myeloid, Acute
Chemosensitization With Plerixafor Plus G-CSF in Acute Myeloid Leukemia
This study is designed to test the combination of Plerixafor with G-CSF for chemosensitization in patients with relapsed or refractory AML.
- Trial name
- NCT00906945
- Testing
- G-CSF, Plerixafor, Mitoxantrone
- Where
- 3 sites in United States
- Volunteers
- 39 people
- Sponsor
- Washington University School of Medicine
Refractory Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
This will be an open-label, Phase 1B/2A, study to characterize the efficacy, safety, pharmacokinetics, and pharmacodynamics of fosciclopirox administered alone and in combination with cytarabine in patients with R/R AML with up…
- Trial name
- NCT04956042
- Testing
- Fosciclopirox, Fosciclopirox + Cytarabine
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- CicloMed LLC
Acute Myeloid Leukemia
Conventional and Experimental Chemotherapy With Allogeneic Transplant in Young Patients With Acute Myeloid Leukaemia
The purpose of this study is evaluate patients with acute myeloid leukemia (<=66 years), treated with conventional and experimental chemotherapy following allogeneic transplantation.
- Trial name
- AML (NCT01785953)
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliera San Giovanni Battista
Leukemia
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT05309213
- Testing
- IM19 CAR-T cells
- Volunteers
- 58 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.